CX Institutional’s Jazz Pharmaceuticals JAZZ Stock Holding History

CX Institutional’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.22M	Sell	9,216 -390	-4%	-$85.4K	0.06%	241
2026 Q1	$1.82M	Sell	9,606 -1,226	-11%	-$214K	0.06%	265
2025 Q4	$1.84M	Sell	10,832 -50,355	-82%	-$7.72M	0.05%	210
2025 Q3	$8.06M	Buy	61,187 +18,295	+43%	+$2.19M	0.24%	100
2025 Q2	$4.55M	Buy	42,892 +8,124	+23%	+$882K	0.16%	144
2025 Q1	$4.32M	Buy	+34,768	New	+$4.54M	0.16%	132
2019 Q3	–	Sell	-7	Closed	-$1K	–	877
2019 Q2	$1K	Buy	+7	New	+$941	﹤0.01%	861

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

CX Institutional's JAZZ Position: Q2 2026 in Review

CX Institutional reduced its Jazz Pharmaceuticals (JAZZ) stake by 4.1% in Q2 2026, selling an estimated $85.4K and leaving 9,216 shares worth $2.22M. The position accounts for 0.06% of the portfolio, ranked #241.

CX Institutional first reported a position in JAZZ in Q2 2019 and has held it in 7 quarters since. The position peaked at $8.06M in Q3 2025. 82 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

CX Institutional held 9,216 shares of Jazz Pharmaceuticals worth $2.22M as of Q2 2026.
CX Institutional sold 390 Jazz Pharmaceuticals shares in Q2 2026, an estimated $85.4K.
Jazz Pharmaceuticals made up 0.06% of CX Institutional's portfolio in Q2 2026, its #241 holding.
CX Institutional first reported a position in Jazz Pharmaceuticals in Q2 2019 and has held it in 7 quarters since.
CX Institutional's Jazz Pharmaceuticals position peaked at $8.06M in Q3 2025.
82 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.